GlassScriptPhysician profile
Sarah Machowicz
NPI 1750870101
$1,238.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.06 · 2022: $432 · 2023: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.61 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $181.10 | 2020-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $176.63 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.17 | 2022-2023 | |
| Alkermes, INC. | $106.54 | 2020-2023 | Aristada, Lybalvi |
| Corium, LLC | $91.51 | 2022-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $89.53 | 2022-2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $87.12 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $69.90 | 2023 | Sertraline Hcl, Loreev Xr |
| Tris Pharma INC | $60.44 | 2023 | Dyanavel Xr |
| Abbvie INC. | $59.69 | 2022-2023 | |
| Bausch Health US, LLC | $56.24 | 2022-2023 | Aplenzin |
| Lundbeck LLC | $52.85 | 2022-2023 | Brintellix, Rexulti |
| Validus Pharmaceuticals LLC | $41.99 | 2022-2023 | Equetro |
| Takeda Pharmaceuticals U.S.A., INC. | $40.67 | 2022-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $14.19 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Machowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.